市場調査レポート

院内感染治療薬市場(薬剤別:抗菌剤、抗ウイルス剤、抗真菌剤、感染種類別:院内感染肺炎、尿路感染、医長疾患、血流感染、手術部位感染、その他):世界の業界分析、パイプライン分析、規模、シェア、成長、動向および予測

Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

発行 Transparency Market Research 商品コード 314944
出版日 ページ情報 英文 121 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
院内感染治療薬市場(薬剤別:抗菌剤、抗ウイルス剤、抗真菌剤、感染種類別:院内感染肺炎、尿路感染、医長疾患、血流感染、手術部位感染、その他):世界の業界分析、パイプライン分析、規模、シェア、成長、動向および予測 Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日: 2014年09月01日 ページ情報: 英文 121 Pages
概要

院内感染は医療関連感染ともいわれ、病院や医療機関に入院中の患者が発症する感染症です。複数の抗菌剤が幅広い院内感染治療効果を証明されています。

当レポートは、院内感染治療薬市場について、薬剤別、感染種類別、および地域別に分析し、市場の現状と市場の機会、および参入企業のプロファイルなどをまとめています。。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 院内感染治療薬市場概要

  • 概要
  • イベント影響分析
  • 市場促進因子
  • 市場阻害因子
  • 市場の機会
  • バリューチェーン分析
  • ポーターズファイブフォース分析
  • 主要企業による市場シェア
  • 市場魅力度分析
  • 競合環境

第4章 薬剤別院内感染治療薬市場

  • 概要
  • 抗菌剤
  • 抗ウイルス剤
  • 抗真菌剤
  • パイプライン分析:市場予測

第5章 院内感染治療薬市場:主な感染別

  • 概要
  • 院内感染肺炎
  • 手術部位感染
  • 尿路感染
  • 胃腸疾患
  • 血流感染
  • その他

第6章 地域別院内感染治療薬市場

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 提言

第8章 企業プロファイル

図表

目次

Title: Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.

This report on hospital infection therapeutics, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections (HCAIs), or nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. A Hospital infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present. This report comprises of an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global hospital infection therapeutics market with respect to market segments based on type of drugs used, major hospital infections and geographic regions.

The market for hospital infection therapeutics is segmented into three major therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also segmented on the basis of major hospital infection types, into six major categories, namely, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The market has been extensively analyzed on the basis of the usefulness, effectiveness and sales revenue of major drug types as well as geographic prevalence of major types of hospital infections. The market size and forecast in terms of USD million for each drug as well as major infection types has been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.

Geographically, the hospital infection therapeutics market has been categorized into four regions namely, North America, Europe, Asia Pacific, and Rest of the World (ROW). The market size and forecast for each of these regions has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period. Major pipeline drugs that have been included in the report are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and Tedizolid. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of this market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and competitive analysis of the key players in 2013 in the global hospital infection therapeutics market.

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital infection therapeutics market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi.

The global hospital infection therapeutics market is segmented as follows:

Hospital Infection Therapeutics Market, by Drug Type

  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

Hospital Infection Therapeutics Market, by Major Infections

  • Hospital-Acquired Pneumonia
  • Surgical Site Infections
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Other Hospital Infections

Hospital Infection Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Assumptions

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Global Hospital Infection Therapeutics Market
  • 2.2. Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)

Chapter 3 - Hospital Infection Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Event Impact Analysis
  • 3.3. Market Drivers
    • 3.3.1. High Prevalence of Various Hospital Infections Driving the Demand for Anti-infective Drugs
    • 3.3.2. High Susceptibility of Neonatal Population in a Healthcare Setting Giving Rise to Different Hospital Infections
    • 3.3.3. Lack of Skilled Nursing Staff in Developing and Underdeveloped Economies is Increasing the Prevalence of HAIs
  • 3.4. Market Restraints
    • 3.4.1. Increasing Hospital Surveillance and Infection Control Programs in Developed Countries Leading to a Decline in Number of Hospital Infections
    • 3.4.2. Increasing Number of Multi-drug resistant Bacterial Strains making Presently Available Antibacterial Drugs Obsolete
  • 3.5. Market Opportunities
    • 3.5.1. High Number of Pipeline Drug Molecules for Specific Treatment of HAIs
    • 3.5.2. Increasing Incidences of Hospital Infections and High Unmet Needs in Low to Medium Income Countries of the World
  • 3.6. Value Chain Analysis
  • 3.7. Porter's Five Forces Analysis: Global Hospital Infection Therapeutics Market
    • 3.7.1. Bargaining Power of Suppliers
    • 3.7.2. Bargaining Power of Buyers
    • 3.7.3. Threat of Substitutes
    • 3.7.4. Threat of New Entrants
    • 3.7.5. Competitive Rivalry
  • 3.8. Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography
  • 3.9. Competitive Landscape
    • 3.9.1. Market Share Analysis by Key Players: Hospital Infection Therapeutics Market, 2013 (Value %)

Chapter 4 - Hospital Infection Therapeutics Market, by Drug Type

  • 4.1. Overview
    • 4.1.1. Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 - 2020 (USD Million)
    • 4.1.2. Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
  • 4.2. Antibacterial Drugs
    • 4.2.1. Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.3. Antiviral Drugs
    • 4.3.1. Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.4. Antifungal Drugs
    • 4.4.1. Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • 4.5. Pipeline Analysis: Market Forecast
    • 4.5.1. Amikacin Inhale
      • 4.5.1.1. Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.2. CAZ AVI (Ceftazidime/avibactum)
      • 4.5.2.1. Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.3. Ceftolozane/Tazobactam
      • 4.5.3.1. Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.4. Dalvance (dalbavancin)
      • 4.5.4.1. Global Dalvance (dalbavancin) Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.5. Delafloxacin (RX-3341)
      • 4.5.5.1. Global Delafloxacin Market Revenue (Expected), 2015 - 2020 (USD Million)
    • 4.5.6. Eravacycline (TP-434)
      • 4.5.6.1. Global Eravacycline Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.7. MK-3415A
      • 4.5.7.1. Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD Million)
    • 4.5.8. Oritavancin
      • 4.5.8.1. Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.9. Plazomicin
      • 4.5.9.1. Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.10. Surotomycin (CB-315)
      • 4.5.10.1. Global Surotomycin Market Revenue (Expected), 2017 - 2020 (USD Million)
    • 4.5.11. Tedizolid (TR-701)
      • 4.5.11.1. Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD Million)

Chapter 5 - Hospital Infection Therapeutics Market, by Major Infections

  • 5.1. Overview
    • 5.1.1. Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 - 2020 (USD Million)
    • 5.1.2. Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
  • 5.2. Hospital-Acquired Pneumonia (HAP)
    • 5.2.1. Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.3. Surgical Site Infections (SSIs)
    • 5.3.1. Global Surgical Site Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.4. Urinary Tract Infections (UTIs)
    • 5.4.1. Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.5. Gastrointestinal Disorders
    • 5.5.1. Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.6. Bloodstream Infections
    • 5.6.1. Global Bloodstream Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 5.7. Other Hospital Infections
    • 5.7.1. Global Other Hospital Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 6 - Hospital infection therapeutics Market, by Geography

  • 6.1. Overview
    • 6.1.1. Global Hospital infection therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • 6.5. Rest of the World (RoW)
    • 6.5.1. RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 - Recommendations

Chapter 8. -Company Profiles

  • 8.1. Actavis plc
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
    • 8.1.5. Recent Developments
  • 8.2. AstraZeneca plc
    • 8.2.1. Company Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategies
    • 8.2.5. Recent Developments
  • 8.3. Bayer AG
    • 8.3.1. Company Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategies
    • 8.3.5. Recent Developments
  • 8.4. Bristol-Myers Squibb Company
    • 8.4.1. Company Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategies
    • 8.4.5. Recent Developments
  • 8.5. Cubist Pharmaceuticals, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategies
    • 8.5.5. Recent Developments
  • 8.6. GlaxoSmithKline plc
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategies
    • 8.6.5. Recent Developments
  • 8.7. Johnson & Johnson Services, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Overview
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategies
    • 8.7.5. Recent Developments
  • 8.8. Merck & Co., Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Financial Overview
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategies
    • 8.8.5. Recent Developments
  • 8.9. Pfizer, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Overview
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategies
    • 8.9.5. Recent Developments
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Financial Overview
    • 8.10.3. Product Portfolio
    • 8.10.4. Business Strategies
    • 8.10.5. Recent Developments

List of Figures

  • FIG. 1: Hospital Infection Therapeutics: Market Segmentation
  • FIG. 2: Global Hospital Infection Therapeutics Market, by Drug Type, 2013 (USD Million)
  • FIG. 3: Global Hospital Infection Therapeutics Market, by Major Infections, 2013 (USD Million)
  • FIG. 4: Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %)
  • FIG. 5: Global Hospital Infection Therapeutics Market: Event Impact Analysis
  • FIG. 6: Global Hospital Infection Therapeutics Market, Value Chain Analysis
  • FIG. 7: Porter's Five Forces Analysis: Global Hospital Infection Therapeutics Market, 2012 - 2020
  • FIG. 8: Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography (2013)
  • FIG. 9: Market Share Analysis: Hospital Infection Therapeutics Market, 2013 (Value %)
  • FIG. 10: Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %)
  • FIG. 11: Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12: Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13: Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14: Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 15: Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 16: Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 17: Global Dalvance (Dalbavancin) Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 18: Global Delafloxacin Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 19: Global Eravacycline Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 20: Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD Million)
  • FIG. 21: Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 22: Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 23: Global Surotomycin Market Revenue (Expected), 2017 - 2020 (USD Million)
  • FIG. 24: Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD Million)
  • FIG. 25: Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %)
  • FIG. 26: Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 27: Global Surgical Site Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 28: Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 29: Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 30: Global Bloodstream Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 31: Global Other Hospital Infection Therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 32: North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 33: Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 34: Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 35: RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 36: Actavis plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 37: AstraZeneca plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 38: Bayer AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 39: Bristol-Myers Squibb Company: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 40: Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 41: GlaxoSmithKline plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 42: Johnson & Johnson: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 43: Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 44: Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 45: Sanofi: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1: Market Snapshot: Global Hospital Infection Therapeutics Market
  • TABLE 2: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 - 2020 (USD Million)
  • TABLE 3: Comparison of Major Resistant Bacterial Strains Prevalence Against Major Therapeutic Drug Classes, in Respective Years (2008 & 2013)
  • TABLE 4: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 - 2020 (USD Million)
  • TABLE 5: Global Hospital infection therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top